AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32271053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 108
Study 32271053 — intervention group
Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 108
Study 36477032 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy only (experimental group)
Number of subjects: 17980
Study 36477032 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy and MRI-targeted biopsy (reference group)
Number of subjects: 17980
Study 36477032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17980
Study 34319986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention (improved dual-pit latrine, tools for child/animal feces management, behavioral messaging)
Number of subjects: 1405
Study 34319986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sanitation intervention)
Number of subjects: 1405
Study 32749941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adjuvant chemotherapy and radiotherapy (CTRT)
Number of subjects: 423
Study 32749941 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 423
Study 35545644 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal cord stimulation (tSCS)
Number of subjects: 10
Study 35545644 — intervention group
Group type: COMPARATOR
Intervention: Buspirone (busp)
Number of subjects: 10
Study 35545644 — intervention group
Group type: COMPARATOR
Intervention: Buspirone plus tSCS
Number of subjects: 10
Study 32247072 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous intervention (PPCI) in patients with reciprocal ST-segment depression (Group A)
Number of subjects: 112
Study 32247072 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous intervention (PPCI) in patients without reciprocal ST-segment depression (Group B)
Number of subjects: 112
Study 36048026 — intervention group
Group type: EXPERIMENTAL
Intervention: axi-cel
Number of subjects: 0
Study 36048026 — intervention group
Group type: COMPARATOR
Intervention: liso-cel
Number of subjects: 0
Study 33600899 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 215
Study 33600899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes measures (PROMs)
Number of subjects: 215
Study 32985001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented barley - wheat flour compound noodle (FBWN)
Number of subjects: 0
Study 32985001 — intervention group
Group type: COMPARATOR
Intervention: Whole wheat noodles (WWN)
Number of subjects: 0
Study 35905985 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise
Number of subjects: 0
Study 35905985 — intervention group
Group type: COMPARATOR
Intervention: Best practice advice
Number of subjects: 0
Study 35905985 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 0
Study 35905985 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home exercise
Number of subjects: 0
Study 33463899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervals (30 minutes, 10, 1-minute intervals at 85% heart-rate reserve)
Number of subjects: 9
Study 33463899 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (45 minutes at 50% heart-rate reserve)
Number of subjects: 9
Study 33463899 — intervention group
Group type: COMPARATOR
Intervention: Control (30 minutes quiet rest)
Number of subjects: 9
Study 32869580 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Hydroprednisone (2 mg•kg‐1•d‐1)
Number of subjects: 60
Study 32869580 — intervention group
Group type: COMPARATOR
Intervention: Hydroprednisone (2 mg•kg‐1•d‐1)
Number of subjects: 60
Study 35441396 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 1082
Study 35441396 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate with NSAIDs
Number of subjects: 1082
Study 35441396 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate without NSAIDs
Number of subjects: 1082
Study 35441396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1082
Study 33930795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on easily obtainable parameters
Number of subjects: 1620
Study 33930795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1620
Study 32035708 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 0
Study 32035708 — intervention group
Group type: COMPARATOR
Intervention: Tetravalent Inactivated Influenza Vaccine (TIV)
Number of subjects: 0
Study 32035708 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination followed bacterial inoculation
Number of subjects: 0
Study 35357766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MMP9 levels in quintile Q5 (highest quintile)
Number of subjects: 3014
Study 35357766 — intervention group
Group type: COMPARATOR
Intervention: Baseline MMP9 levels in quintile Q3 (reference group)
Number of subjects: 3014
Study 35357766 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MMP9 ratios
Number of subjects: 3014
Study 36208364 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg once daily
Number of subjects: 1776
Study 36208364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1776
Study 34704974 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive palatal stents (CPSGs)
Number of subjects: 144
Study 34704974 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 144
Study 32343000 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 49
Study 32343000 — intervention group
Group type: COMPARATOR
Intervention: Autologous placebo
Number of subjects: 49
Study 35786390 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion (EASI)
Number of subjects: 150
Study 35786390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal isoniazid (INH)
Number of subjects: 150
Study 32701172 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 22
Study 32653075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MF–IND (320 μg, 150 μg) once daily
Number of subjects: 2216
Study 32653075 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose MF–IND (160 μg, 150 μg) once daily
Number of subjects: 2216
Study 32653075 — intervention group
Group type: COMPARATOR
Intervention: High-dose MF (800 μg [400 μg twice daily])
Number of subjects: 2216
Study 32653075 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose MF (400 μg once daily)
Number of subjects: 2216
Study 32653075 — intervention group
Group type: COMPARATOR
Intervention: High-dose FLU–SAL (500 μg, 50 μg) twice daily
Number of subjects: 2216
Study 35022769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookah lounges
Number of subjects: 479
Study 35022769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vape shops
Number of subjects: 479
Study 35022769 — intervention group
Group type: EXPERIMENTAL
Intervention: All tobacco retailers
Number of subjects: 479
Study 34858404 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac
Number of subjects: 0
Study 35379298 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes management strategy using an information board and a mobile application
Number of subjects: 1440
Study 35379298 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1440
Study 34650220 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based inference of retinal function using deep-learning software
Number of subjects: 57
Study 34650220 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based inference of retinal function with patient-specific baseline data
Number of subjects: 57
Study 34650220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of month 7-8 post-treatment retinal sensitivity from baseline SD-OCT data
Number of subjects: 57
Study 32650533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemannan
Number of subjects: 50
Study 32650533 — intervention group
Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 50
Study 36053133 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured scenes with four pairs of co-occurring distractor shapes
Number of subjects: 1140
Study 36053133 — intervention group
Group type: COMPARATOR
Intervention: Unstructured scenes with eight distractor shapes randomly partitioned into four pairs
Number of subjects: 1140
Study 33712062 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-informed complementary trial (PICT) design
Number of subjects: 0
Study 33712062 — intervention group
Group type: COMPARATOR
Intervention: Traditional randomized controlled trials (RCTs)
Number of subjects: 0
Study 33712062 — intervention group
Group type: COMPARATOR
Intervention: Preference-informed designs
Number of subjects: 0
Study 32779505 — intervention group
Group type: EXPERIMENTAL
Intervention: Epeleuton 2 g/day
Number of subjects: 96
Study 32779505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 615730633 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral diazepam bolus
Number of subjects: 96
Study 615730633 — intervention group
Group type: COMPARATOR
Intervention: Parenteral diazepam continuous infusion
Number of subjects: 96
Study 615730633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (bolus and infusion)
Number of subjects: 96
Study 36098361 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium corneum gigeriae galli
Number of subjects: 68
Study 36098361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 34377934 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant clodronate (1600 mg daily for 3 years)
Number of subjects: 1883
Study 34377934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1883
Study 32286643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (20 µg, n = 201)
Number of subjects: 400
Study 32286643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 199)
Number of subjects: 400
Study 35033949 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 140
Study 35033949 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 140
Study 35033949 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 140
Study 33045330 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) 133 mg with 7.5 mL of 0.5% and 7.5 mL of 0.25% plain bupivacaine
Number of subjects: 104
Study 33045330 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 25 mL of 0.5%
Number of subjects: 104
Study 35616780 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 19
Study 35616780 — intervention group
Group type: COMPARATOR
Intervention: Video exercise
Number of subjects: 19
Study 34334695 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb injuries
Number of subjects: 6662
Study 34334695 — intervention group
Group type: COMPARATOR
Intervention: Lower limb injuries
Number of subjects: 6662
Study 34334695 — intervention group
Group type: COMPARATOR
Intervention: Spica casts (single leg)
Number of subjects: 6662
Study 34334695 — intervention group
Group type: COMPARATOR
Intervention: Spica casts (one and a half leg)
Number of subjects: 6662
Study 34334695 — intervention group
Group type: COMPARATOR
Intervention: Spica casts (two leg)
Number of subjects: 6662
Study 34334695 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced daycare facilities (>5 years)
Number of subjects: 6662
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses reported in HF RCTs
Number of subjects: 261
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup effect claims for primary outcome
Number of subjects: 261
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction testing for subgroup claims
Number of subjects: 261
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Credibility criteria satisfaction
Number of subjects: 261
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Justification of subgroup choice
Number of subjects: 261
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Power to detect differences within subgroups
Number of subjects: 261
Study 33254286 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of funding source on reporting
Number of subjects: 261
Study 36116033 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited TAVR
Number of subjects: 142
Study 33229024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Snaith-Hamilton Pleasure Scale (SHAPS)
Number of subjects: 5054
Study 33270911 — intervention group
Group type: EXPERIMENTAL
Intervention: chronoIFLO5 (irinotecan 180 mg/sqm, oxaliplatin 80 mg/sqm, fluorouracil 2800 mg/sqm, leucovorin 1200 mg/sqm) administered every 3 weeks for 5 days
Number of subjects: 193
Study 33270911 — intervention group
Group type: EXPERIMENTAL
Intervention: chronoIFLO5
Number of subjects: 193
Study 35416742 — intervention group
Group type: EXPERIMENTAL
Intervention: face-to-face plus monitored home exercise
Number of subjects: 150
Study 35416742 — intervention group
Group type: EXPERIMENTAL
Intervention: only monitored home-based exercise
Number of subjects: 150
Study 35416742 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 150
Study 32205276 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D printed porous titanium implants
Number of subjects: 49
Study 32205276 — intervention group
Group type: COMPARATOR
Intervention: PEEK with autograft (control)
Number of subjects: 49
Study 616854365 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension (KT)
Number of subjects: 36
Study 616854365 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping without tension (placebo)
Number of subjects: 36
Study 616854365 — intervention group
Group type: COMPARATOR
Intervention: Control group (ten minutes of rest)
Number of subjects: 36
Study 33517368 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval practice (SRP) with self-generation booster
Number of subjects: 41
Study 33517368 — intervention group
Group type: COMPARATOR
Intervention: Massed study control condition
Number of subjects: 41
Study 33517368 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval practice (SRP)
Number of subjects: 41
Study 32917189 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-step teaching method
Number of subjects: 68
Study 32917189 — intervention group
Group type: COMPARATOR
Intervention: All-in-one teaching method
Number of subjects: 68
Study 35105638 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi survey
Number of subjects: 53
Study 34388297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg/d
Number of subjects: 17
Study 35100917 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin (60 mg/m2 administered on days 1 and 3, 30 mg/m2 each time) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Number of subjects: 114
Study 35100917 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with cisplatin (60 mg/m2 intravenously) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Number of subjects: 114
Study 35100917 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC group
Number of subjects: 114
Study 35100917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 33836364 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week psychoeducation intervention
Number of subjects: 12
Study 33836364 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 12
Study 35346549 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 14 days
Number of subjects: 160
Study 35346549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32796950 — intervention group
Group type: EXPERIMENTAL
Intervention: NRM-J index applied to patients in the validation set
Number of subjects: 2344
Study 32796950 — intervention group
Group type: EXPERIMENTAL
Intervention: NRM-J index
Number of subjects: 2344
Study 33345865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 29
Study 33345865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate
Number of subjects: 29
Study 33345865 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of previous corticosteroid infiltrations
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time from symptom onset to surgery
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker status
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of prior lumbosacral fusion (LSF)
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia
Number of subjects: 60
Study 33428860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 60
Study 32553717 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg/emtricitabine (FTC) 200 mg, 7 doses/week (perfect adherence)
Number of subjects: 28
Study 32553717 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg/emtricitabine (FTC) 200 mg, 4 doses/week (moderate adherence)
Number of subjects: 28
Study 32553717 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg/emtricitabine (FTC) 200 mg, 2 doses/week (low adherence)
Number of subjects: 28
Study 35112974 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg/day)
Number of subjects: 84
Study 35112974 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 33125510 — intervention group
Group type: EXPERIMENTAL
Intervention: AcceleDent® Aura (vibrational forces)
Number of subjects: 20
Study 33125510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibrational forces)
Number of subjects: 20
Study 32687185 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical segmentectomy
Number of subjects: 370
Study 32687185 — intervention group
Group type: COMPARATOR
Intervention: Wedge resection
Number of subjects: 370
Study 37206222 — intervention group
Group type: EXPERIMENTAL
Intervention: KCZ‐ILs (KCZ, 4.72 mg/g)
Number of subjects: 36
Study 37206222 — intervention group
Group type: COMPARATOR
Intervention: Daktarin® (control group; KCZ, 20 mg/g)
Number of subjects: 36
Study 37206222 — intervention group
Group type: EXPERIMENTAL
Intervention: KCZ‐ILs
Number of subjects: 36
Study 37206222 — intervention group
Group type: COMPARATOR
Intervention: Daktarin®
Number of subjects: 36
Study 34289330 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus vouchers for attendance (VOU)
Number of subjects: 460
Study 34289330 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus text reminders (REM)
Number of subjects: 460
Study 34289330 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus vouchers and text reminders (VOU + REM)
Number of subjects: 460
Study 34289330 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (STD)
Number of subjects: 460
Study 32847776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D0, N = 22)
Number of subjects: 88
Study 32847776 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg (D30, N = 22)
Number of subjects: 88
Study 32847776 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (D60, N = 22)
Number of subjects: 88
Study 32847776 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 90 mg (D90, N = 22)
Number of subjects: 88
Study 36284450 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal cooling using the ensoETM® device to keep esophageal temperature at 4°C during ablation
Number of subjects: 188
Study 36284450 — intervention group
Group type: COMPARATOR
Intervention: Standard practice using a single-sensor temperature probe
Number of subjects: 188
Study 36284450 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal cooling using the ensoETM® device
Number of subjects: 188
Study 34953193 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush with reciprocating and pulsating movements
Number of subjects: 180
Study 34953193 — intervention group
Group type: COMPARATOR
Intervention: Manual brush with an even brush field
Number of subjects: 180
Study 34953193 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual brush with a multi-level brush field
Number of subjects: 180
Study 34953193 — intervention group
Group type: COMPARATOR
Intervention: Electric toothbrush
Number of subjects: 180
Study 34021349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study 34592075 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG) underwent 20 min of acupuncture/day for 10 days
Number of subjects: 60
Study 34592075 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) underwent normal routine for 10 days
Number of subjects: 60
Study 34592075 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 60
Study 35064385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 40 ppm
Number of subjects: 32
Study 35064385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normoxia)
Number of subjects: 32
Study 35064385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 32
Study 35064385 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance trained individuals
Number of subjects: 32
Study 33796915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and atezolizumab
Number of subjects: 53
Study 33796915 — intervention group
Group type: COMPARATOR
Intervention: High PLR (> 119.23)
Number of subjects: 53
Study 33796915 — intervention group
Group type: COMPARATOR
Intervention: Low PLR (≤ 119.23)
Number of subjects: 53
Study 33796915 — intervention group
Group type: COMPARATOR
Intervention: High PLR in external validation set
Number of subjects: 53